SBRT Appears Effective for Oligometastatic Prostate Cancer
Stereotactic body radiation therapy (SBRT) appears to be an effective treatment for oligometastatic disease in patients with recurrent prostate cancer, a... Read More
Gene Variant May Affect Response to Abiraterone in Certain Men with Prostate Cancer
A new study has shown that a genetic anomaly found in certain men with prostate cancer — a variant in HSD3B1 —... Read More
Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk Prostate Cancer
Partial prostate treatment with MRI-guided brachytherapy may lead to poor outcomes long-term among patients with intermediate-risk prostate cancer, according to a... Read More
New Therapeutic Directions in the Management of Prostate Cancer
Efforts to unravel prostate cancer’s genetic fingerprints lag behind other cancers, notably breast cancer, experts agree. But, mutations seen in the... Read More
Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL
Enzalutamide delays metastasis in men with non-metastatic castration̶resistant prostate cancer (CRPC) without worsening health-related quality of life (HRQoL) and significantly decreases the... Read More
Active Surveillance May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer
New findings support the safety of including selected men with Gleason 3+4 prostate cancer in active surveillance (AS) programs, Australian researchers reported... Read More
Diet and Dosage: How Much Could Patients Save?
The authors of a recent prostate cancer study claim that a drug manufacturer and the US Food and Drug Administration... Read More
Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years
The Prostate Cancer Prevention Trial (PCPT) showed that the use of finasteride, a 5-alpha-reductase inhibitor, for 7 years reduced the... Read More
Adding Mitoxantrone to Adjuvant ADT Not Recommended for High-Risk Prostate Cancer
Adding mitoxantrone and prednisone (MP) to adjuvant androgen-deprivation therapy (ADT) does not improve overall survival (OS) or disease-free survival (DFS)... Read More
Circulating Tumor Cell Count May Predict for Overall Survival in Prostate Cancer
Circulating tumor cell (CTC) counts correspond with overall survival (OS) among patients with early-phase metastatic castration-resistant prostate cancer (mCRPC), according to a study... Read More